Search This Blog

Tuesday, February 11, 2020

Interpace Bio up 6% on improved reimbursement for ThyraMIR

Thinly traded nano cap Interpace Biosciences (NASDAQ:IDXG) perks up 6% premarket on light volume in reaction to its announcement that Medicare has upped its reimbursement for ThyraMIR miRNA classifier from ~$1,800 to $3,000.
Medicare beneficiaries account for ~30% of ThyraMIR test volume
https://seekingalpha.com/news/3540467-interpace-bio-up-6-on-improved-reimbursement-for-thyramir

Advaxis teams up with Personalis for ADXS-503 program

Advaxis (NASDAQ:ADXS) and Personalis (NASDAQ:PSNL) have collaborated to leverage Personalis’ ImmunoID NeXT Platform in Advaxis’ ongoing Phase 1/2 ADXS-503 (HOT Lung) program evaluating ADXS-503 alone and in combination with pembrolizumab in patients with non-small cell lung cancer (NSCLC).
Under the terms of the expanded agreement, Personalis will conduct comprehensive tumor immunogenomic profiling to enable the identification of predictive composite biomarkers and/or signatures of response, as well as the broad evaluation of potential mechanisms of therapy resistance.
The platform is an end-to-end solution for immuno- and precision oncology biomarker discovery and CDx development.
This new agreement builds upon the prior two-year collaboration for the genomic analysis of clinical tumor samples to manufacture the Company’s ADXS-NEO drug construct neoantigen-directed immunotherapy to treat a variety of late stage cancers.
ADXS and PSNL shares are up 13% and 8% premarket, respectively.
https://seekingalpha.com/news/3540482-advaxis-teams-up-personalis-for-adxsminus-503-program-shares-up-13-premarket

Moderna advancing CMV vaccine, adds coronavirus vaccine to pipeline

Moderna (NASDAQ:MRNA) announces that enrollment in its Phase 2 clinical trial evaluating its mRNA vaccine (mRNA-1647) against cytomegalovirus (CMV) is proceeding ahead of schedule with preliminary data now expected in Q3.
It has added three new pipeline programs: mRNA-1189 (Epstein-Barr vaccine), mRNA-1345 (RSV vaccine) and mRNA-1273 (coronavirus vaccine).
It also announces that the first patient has been enrolled in a Phase 1/2 study of mRNA-3704 in patients with a rare inborn error of metabolism called isolated methylmalonic acidemia due to MUT deficiency, an Orphan Drug-, Fast Track- and Rare Pediatric Disease-tagged indication in the U.S.
Shares down 6% premarket in reaction to its planned equity offering.
https://seekingalpha.com/news/3540483-moderna-advancing-cmv-vaccine-adds-coronavirus-vaccine-to-pipeline

Hundreds of Chinese businesses seek billions in loans to deal with coronavirus

More than 300 Chinese companies are seeking bank loans totaling at least 57.4 billion yuan ($8.2 billion) to help to soften the impact of the coronavirus outbreak, two banking sources said.
Authorities have cordoned off cities, suspended transport links and shuttered facilities where crowds gather, hammering economic growth that one senior economist said could slow to 5% or less in the first quarter.
Extended factory closures, meanwhile, will slow manufacturing and weigh on global supply chains.
Among the prospective borrowers are food delivery giant Meituan Dianping (3690.HK), smartphone maker Xiaomi Corp (1810.HK), ride-hailing provider Didi Chuxing Technology Co, facial recognition start-up Megvii Technology Inc and internet security business Qihoo 360 Technology Co, the sources said, adding that the companies seeking loans were either involved in the control of the epidemic or had been hardest hit.
China is fighting to contain the epidemic, which has killed more than 900 people in the country and infected more than 40,000.
The companies seeking loans in the Chinese capital are likely to get fast-track approvals and preferential interest rates, said the sources, who received copies of two lists of company names sent to Beijing banks by the city government’s finance bureau.
The two lists also contained the size of loans sought.

There is no official data showing the total loans Chinese companies are seeking nationwide to weather the outbreak.
“Banks will have the final say on lending decisions,” one of the sources said. “The interest rates are likely to be on par with those offered to banks’ top clients.”
Xiaomi, the world’s fourth-biggest smartphone maker, is seeking 5 billion yuan ($716 million) in loans to produce and sell medical equipment including masks and thermometers, according to the lists.
Meituan Dianping is seeking 4 billion yuan, partly to help finance free food and deliveries to medical staff in Wuhan, the epicenter of the outbreak in central Hubei province.
Privately held Didi Chuxing, “severely impacted by the virus outbreak”, is seeking 50 million yuan.

FACIAL RECOGNITION

Exchange disclosures showed that Xiaomi’s third-quarter revenue growth slowed, but gross profit surged 25.2% year on year to 8.2 billion yuan. Meituan Dianping has been profitable for the past two quarters.

Beijing-based Qihoo 360 is seeking 1 billion yuan ($143.3 million) to buy medical-related products and finance work on apps to track and contain the virus.
Facial recognition start-up Megvii applied for 100 million yuan to develop technology including means to improve the accuracy of identifying masked individuals in crowds, according to one of the lists.
Megvii declined to confirm the loan or the loan application.
Megvii said it is working to optimize the artificial intelligence-enabled body temperature screening product it launched last week to help fight the virus, by spotting and locating people in a crowd who have elevated temperatures, even if they are wearing masks. Megvii does not verify the personal identities of people wearing masks.
Beijing-based Megvii has sought to raise funds through an initial public offering in Hong Kong, but its efforts were initially delayed after its inclusion on a U.S. trade blacklist over alleged involvement in human rights violations related to Beijing’s clampdown on Uighurs in China’s Xinjiang region. The company has said it “strongly objected” to the U.S. move.
Meituan Dianping, Didi and Xiaomi declined to comment. Qihoo 360 did not immediately respond to requests for comment.
The financial bureau of the Beijing city government did not respond to an emailed request for comment.
The finance bureau previously said that businesses seeking financial support could ask for its help.
Companies on the bureau’s lists also include vegetable market operators, ambulance manufacturers, environmental protection firms and other businesses key to maintaining food supplies and supporting efforts to contain the outbreak. But it was not immediately clear if all of them are creditworthy.
“The banks won’t lend to all because they need to evaluate whether those companies are really able to pay back,” one of the sources said.
China’s central bank has injected cash into the banking system to shore up market confidence, while the banking and insurance watchdog has also urged lenders to lower interest rates.
The local bureaus of the National Development and Reform Commission (NDRC), the top economic planner, and the Ministry of Industry and Information Technology (MIIT) are also compiling lists of affected companies and offering them support.
https://www.reuters.com/article/us-china-health-lending-exclusive/exclusive-hundreds-of-chinese-businesses-seek-billions-in-loans-to-contend-with-coronavirus-sources-idUSKBN204182

Arcturus started at Outperform by Baird

Target $24
https://www.benzinga.com/stock/ARCT/ratings

Leap Therapeutics started at Outperform by Baird

Target $6
https://www.benzinga.com/stock/LPTX/ratings

Novartis lung cancer drug gets priority U.S. review

Novartis has won fast-track U.S. regulatory review for capmatinib (INC280) in a hard-to-treat form of lung cancer, the Swiss drugmaker said on Tuesday.
Capmatinib is a MET inhibitor being evaluated as a treatment for first-line and previously treated patients with locally advanced or metastatic MET exon 14 skipping (METex14) mutated non-small cell lung cancer.
“If approved, capmatinib will be the first therapy to specifically target METex14 mutated advanced lung cancer, a type of lung cancer with a particularly poor prognosis,” Novartis said in a statement.
https://www.reuters.com/article/us-novartis-cancer/novartis-lung-cancer-drug-gets-priority-u-s-review-idUSKBN2050J9